PSE, a supplier of advanced process modeling software and services, plans to become part of Siemens Digital Industries.
Process Systems Enterprise (PSE), a supplier of advanced process modeling software and services, announced in a Sept. 16, 2019 press release that it plans to be acquired by Siemens AG in a transaction scheduled to close in Q4 2019. The 160-member PSE operation will be integrated into the Process Automation Business Unit of Siemens Digital Industries, and the current PSE management team will remain in place.
PSE’s advanced process models, such as its gPROMS technology, are used within digital R&D, design, and operations in pharmaceutical and other process industries. PSE’s tools complement the Siemens portfolio in the process industry sector.
“The combination of high-fidelity predictive models and process data plays an increasingly important role in the digitalization of design and operations in the process industry,” said Eckard Eberle, CEO of the Siemens Process Automation Business Unit, in the press release. “It is important to take the process knowledge that is already available in product and process development and to map it in predictive models, which can then be used to add value in the digitalization environment in every step of the lifecycle. With PSE we will be even better equipped to meet the specific requirements of our process industry customers."
Siemens and PSE collaborated closely for two years before entering a strategic partnership in June 2018, developing new model-based solutions for applications including detailed unit operation design, plant monitoring and performance forecasting, soft sensing, nonlinear model-predictive control, and real-time optimization.
Both companies have agreed not to comment on the financial details of the transaction.
Source: PSE
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.